Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 1998 / Cilt: 3 - Sayı: 1

Effect of ciprofloxacin and granulocyte colony stimulating factor in bactericidal activity of polymorphonuclear leukocytes against Pseudomonas aeruginosa

Siprofloksasin ve granülosit stimüle edici faktörün polimorf nüveli lökositlerin Pseudomonas aeruginosa' ya karşı bakterisidal aktivitesine etkisi

Pages
26–30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Effect of such a combination in patients can be evaluated by large scale clinical trials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The in vitro effect of subinhibitory and inhibitory concentrations of ciprofloxacin and G-CSF on the bactericidal activity of polymorphonuclear leukocytes (PMNL) against Pseudomonas aeruginosa was investigated.
📊
Key Findings & Data:PMNL obtained from healthy volunteers were incubated with different concentrations of G-CSF and ciprofloxacin for 180 min.
💡
Conclusion & Impact:Effect of such a combination in patients can be evaluated by large scale clinical trials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The in vitro effect of subinhibitory and inhibitory concentrations of ciprofloxacin and G-CSF on the bactericidal activity of polymorphonuclear leukocytes (PMNL) against Pseudomonas aeruginosa was investigated. PMNL obtained from healthy volunteers were incubated with different concentrations of G-CSF and ciprofloxacin for 180 min. Although G-CSF showed certain amount of bactericidal effect, this was statistically in-significant when compared with bactericidal activity of PMNL: The minimum inhibitory concentration of ciprofloxacin as well as subinhibitory concentration enhanced the bactericidal activity of PMNL (p<0.05) and the maximal enhancement of activity was observed in combination of inhibitory concentration of ciprofloxacin and 6000 units/ml of G-CSF (p<O.OI). Clinical application of this combination could initially target infections in high risk groups, particularly neutropenic patients or patients with impaired neutrophil functions in whom one can expect to decrease antibiotic dosage and prevent likely toxic effects. Effect of such a combination in patients can be evaluated by large scale clinical trials.

Özet

Çalışmamızda, Siprofloksasin ve granülosit koloni stimule edici faktör (G-CSF)'ün polimorf nüveli lökositlerin (PM N L) Pseudomonas aeruginosa'ya. karşı bakterisidal aktivitesine etkisi araştırıldı. Sağlıklı gönüllülerden elde edilen lökositler farklı konsantrasyonlardaki G-CSF ve siprofloksasin ile 180 dakika boyunca inkübe edildi. G-CSF'nin tek başına verilmesi bir miktar bakterisidal etki göstermekle birlikte, bu etki PMNL'lerin bakterisidal aktivitesinden anlamlı bir fark göstermedi (p>0.05). inhibitor ve subinhibitör konsantrasyonlarda siprofloksasin PMNL'lerin bakterisidal aktivitesini arttırırken (p<0.05), aktivitedeki artış en fazla inhibitor konsantrasyonda siprofloksasin ve 6000 Ü/mL G-CSF kombinasyonunda gözlendi (p<O.OI). G-CSF'nin antibiyotiklerle kombine edilmesinin özellikle nötropenik ya da nötrofil fonksiyonları bozuk hastalarda tercih edilmesi, gerekli antibiyotik dozunun azaltılması ve olası toksik etkilerin önlenmesi açısından önemli olabilir. Bu etkinliğin belirlenmesinde geniş katılımlı klinik çalışmaların yürütülmesine ihtiyaç vardır.

🔖

Cite This Article

ESKİTÜRK, A., ERGİN, Ü. (1998). Effect of ciprofloxacin and granulocyte colony stimulating factor in bactericidal activity of polymorphonuclear leukocytes against Pseudomonas aeruginosa. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 3 - Sayı: 1, 26–30. https://ajindex.com/articles/224386

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Dale DC, Lies C, Summer W, et al. Granulocyte colonystimulating factor- role and relationships in infectious di-seases. J Infect Dis 1995;172:1061-75. 2.Ferrante A, Thong YH. Optimal conditions for simulta-neous purification of mononuclear and polymorphonuc-lear leukocytes from human peripheral blood by the fi-coll-hypaque method. J Immun Med 1980;36:109-15. 3.National Committee for Laboratory Standards. Dilutionprocedures for susceptibility testing of aerobic bacteria.Approved standarts. M7A3, Villanova: NCCLS Publica-tion, 1993. 4.Welte K, Gabrilove J, Bronchud M, et al. Filgastrim (r-metHuG-CSF): The first ten years. Blood 1996;88:1907-29 5.Cairo MS, Mauss D, Kommareedy S, et al. Prophylacticor simultaneous administration of recombinant humangranulocyte colony stimulating factor in the treatment ofgroup B streptococcal sepsis in neonatal rats. PediatrRes 1990;27:612-6. 6.Silver GM, Gamelli RL, O’ Reilly M. The beneficial effectof granulocyte colony stimulating factor on survival afterPseudomonasburn wound infection. Surgery 1989;106:452-9. 7.Ignes S, Fantin B, Elbim C, et al. Critical influence of ti-ming of administration of granulocyte colony stimulatingfactor on bacterial effect in experimental endocarditisdue to Pseudomonas aeruginosa. Antimicrob AgentsChemother 1995;39:2702-9. 8.Haberstroh J, Breuer H, Lucke I, et al. Effect of recom-binant human granulocyte stimulating factor on hemody-namic and cytokine response in a porcine model of Pse-udomonassepsis. Shock 1995;4:216-24. 9.Dale DC, Bonilla MA, Davis MW, et al. A randomizedcontrolled phase III trial of recombinant human colonystimulating factor for treatment of severe chronic neutro-penia. Blood 1993;81:2496-2501. 10. Maher DW, Lieschke GJ, Green M, et al. Filgastrim inpatients with chemotherapy induced febrile neutropenia.Ann Intern Med 1994;121:492-8. 11. Mitchell PLR, Morland MJ, Dick G, et al. Clinical bene-fits and cost savings of interventional G-CSF therapy inpatients with febrile neutropenia following chemothe-rapy. Blood 1995;86:500 a abstract no. 1989, (Suppl1) 12. Kropec A, Lemmen SW, Grundman HJ, et al. Synergyof simultaneous administration of ofloksasin and granu-locyte colony stimulating factor of Escherichia colibyhuman neutrophils. Infection 1995;23:298-300. 13. Dashner FD, Grundmann H, Anding K, et al. Combinedeffect of human neutrophils, ceftazidime and granulocy-te colony stimulating factor on killing of Escherichia co-li. Eur J Clin Microbiol Infect Dis 1995;14:536-9.